Roche Accu-Chek AI Visibility Market Strategy Report - Healthcare and Medical Devices

Answer Capsule

Roche Accu-Chek ranks third in the October 2026 Healthcare and Medical Devices AI visibility benchmark, with 28.1% valid recommendation coverage behind Abbott FreeStyle at 61.2% and Ascensia CONTOUR at 39.7%. The brand appears in 39.4% of qualified AI responses but converts that presence into a valid recommendation only 28.1% of the time, and that conversion gap defines its market position. Its clearest win is a stable 21.2% top-three placement rate and a net sentiment score of 0.82, while its clearest weakness is a rank-one rate of just 1.1%, meaning it is almost never the first brand AI systems name. The biggest opportunity sits in closing the gap between presence and recommendation on the high-intent prompts where the brand already appears but is not being shortlisted.

Who This Report Is For

This report is written for Roche Accu-Chek commercial, brand, and digital strategy leaders who need to understand how AI search and chat surfaces represent the brand at the recommendation stage of the blood glucose monitoring and diabetes device category.

Report Card

Executive Summary

Roche Accu-Chek enters October 2026 as the third-ranked brand in the Healthcare and Medical Devices benchmark, with 28.1% valid recommendation coverage across 363 qualified observations. The brand was mentioned in 143 of those observations, a raw mention presence rate of 39.4%, but converted only 102 of those mentions into valid recommendations. That gap between presence and recommendation is the defining feature of the brand's AI visibility position: Roche Accu-Chek is seen, but it is not consistently chosen.

The brand's sentiment profile is strong. Of the 143 observations where Roche Accu-Chek appeared, 117 were positive, 26 were neutral, and zero were negative, producing a net sentiment score of 0.82. This is the second-highest net sentiment among tracked brands, behind Ascensia CONTOUR at 0.85 and ahead of Abbott FreeStyle at 0.79. The absence of negative framing is a meaningful asset: when AI systems discuss Roche Accu-Chek, they do so in favorable or neutral terms.

The strongest platform signal for Roche Accu-Chek is Google AI Overviews, where the brand recorded 28 valid recommendations at a 29.2% valid recommendation coverage rate. Google AI Mode follows with 32 valid recommendations at 29.9% coverage. These two Google surfaces account for the majority of the brand's recommendation credit. On Gemini, the brand achieved 35.1% coverage with 26 valid recommendations, its highest platform-level coverage rate.

The clearest platform gap is Perplexity, where Roche Accu-Chek recorded only 1 valid recommendation and a 3.9% coverage rate across 26 observations. The brand also has a rank-one problem across all platforms: its overall rank-one rate is 1.1%, meaning it was the first recommendation in only 4 of 363 qualified observations. By contrast, Ascensia CONTOUR holds a 25.6% rank-one rate and Abbott FreeStyle holds 14.6%. Roche Accu-Chek is consistently in the consideration set but almost never at the top of it.

The brand's coverage has drifted lower over the past two months, easing from 30.4% in September to 28.1% in October, following a decline from 28.5% at the July baseline. Top-three placement has held roughly steady at 21.2%, suggesting the brand is maintaining position within the answers it appears in rather than losing ground within them. The pattern is one of stable placement inside a slowly shrinking recommendation footprint.

What Roche Accu-Chek Is Winning

Questions This Section Answers

• Where does Roche Accu-Chek's AI visibility actually outperform its competitors?
• How stable is the brand's top-three placement compared to its recommendation coverage trend?

Roche Accu-Chek's clearest win is its sentiment profile. With 117 positive mentions, 26 neutral mentions, and zero negative mentions across 143 appearances, the brand has the second-highest net sentiment score in the category at 0.82. AI systems are not surfacing cautionary, comparative, or negative framing about the brand. When Roche Accu-Chek appears, it appears favorably.

The brand's second win is its top-three placement stability. At 21.2% in October, the top-three rate is essentially unchanged from 20.8% at the July baseline. While the brand's overall recommendation coverage has drifted lower, its ability to hold a top-three position within the answers where it is recommended has not deteriorated. The brand's placement quality is intact even as its recommendation footprint contracts.

A third, narrower win is the brand's performance on Gemini. With a 35.1% valid recommendation coverage rate and 26 valid recommendations on that platform, Gemini represents the brand's strongest platform-level recommendation signal. The brand also recorded a 33.8% top-three rate on Gemini, its highest across all platforms.

These wins are real but bounded. The brand does not lead any platform in recommendation coverage, does not lead any cluster, and does not approach the rank-one rates of the category's top two brands. The wins are about framing quality and stability of placement, not about recommendation dominance.

Where Roche Accu-Chek Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why is Roche Accu-Chek mentioned in 39.4% of qualified AI responses but recommended in only 28.1%?
• How concentrated is Roche Accu-Chek's recommendation footprint across AI platforms?
• Which prompt clusters have no qualified data for Roche Accu-Chek, and what does that measurement gap mean?

The most significant gap is rank-one performance. Roche Accu-Chek recorded a rank-one rate of 1.1% in October 2026, meaning it was the first brand recommended in only 4 of 363 qualified observations. Abbott FreeStyle holds a 14.6% rank-one rate and Ascensia CONTOUR holds 25.6%. The brand is in the conversation but is not the answer AI systems lead with. For buyers asking which blood glucose monitor to choose, Roche Accu-Chek is a supporting option, not the headline recommendation.

The second gap is recommendation conversion. The brand appeared in 143 observations but received valid recommendation credit in only 102 of them. That means 41 observations, or 28.7% of the brand's appearances, were mentions without recommendation. The brand is being referenced as context, comparison, or background rather than being shortlisted. This is a conversion problem, not a presence problem.

The third gap is platform concentration. Google AI Overviews and Google AI Mode together account for 60 of the brand's 102 valid recommendations. Perplexity contributed only 1 valid recommendation, and ChatGPT contributed 4. The brand's recommendation footprint is heavily dependent on Google surfaces, leaving it exposed if those surfaces shift their sourcing or ranking behavior.

The fourth gap is the absence of qualified data in the Pricing & Value and Multi-Brand Comparison clusters. The benchmark recorded zero qualified observations in these clusters for October 2026, meaning the brand's performance on cost-related and head-to-head comparison prompts is not measured in the public dataset. This is a measurement gap, not necessarily a performance gap, but it means the brand cannot currently assess how AI systems frame its pricing or how it performs in direct comparisons.

Biggest Opportunity

Questions This Section Answers

• How can Roche Accu-Chek close the gap between its presence rate and its valid recommendation coverage?
• What role does the brand's citation footprint play in its under-recommendation relative to Abbott FreeStyle?

The single biggest opportunity for Roche Accu-Chek is to convert its existing presence into recommendation credit on the prompts where it already appears. The brand is mentioned in 39.4% of qualified observations but recommended in only 28.1%. Closing that gap would move the brand from third place toward second, where Ascensia CONTOUR sits at 39.7% coverage.

The path to that conversion runs through the brand's owned and earned content layer. The benchmark's citation data shows that freestyle.abbott, the Abbott FreeStyle domain, is the third most-cited domain across all AI platform responses in this category, with 200 citations. Roche Accu-Chek's own domain does not appear in the top 10 cited domains. The brand's public evidence layer is not being retrieved and synthesized at the same rate as its primary competitor's. Building a stronger citation architecture around the brand's product pages, comparison content, and third-party validation could increase the likelihood that AI systems surface Roche Accu-Chek as a recommendation rather than a reference.

Competitive Landscape

Questions This Section Answers

• How does Roche Accu-Chek's rank-one rate and average recommended rank compare to Abbott FreeStyle and Ascensia CONTOUR?
• What does the competitive table reveal about where Roche Accu-Chek typically appears when it is recommended?

Abbott FreeStyle holds dominant recommendation power in the category, with Ascensia CONTOUR as the strongest challenger on rank-one placement. Roche Accu-Chek sits in third, visible but under-recommended relative to its presence rate.

Average recommended rank covers rank-eligible recommendations only.

Roche Accu-Chek's position in the table shows a brand with moderate top-three presence but very low rank-one strength. Its average recommended rank of 2.79 places it behind both Abbott FreeStyle and Ascensia CONTOUR, meaning that when it is recommended, it typically appears in the second or third position rather than first.

Prompt Evidence

Google AI Overviews / Best Blood Glucose Monitors and Diabetes Medical Devices Prompt: "What is the best glucose monitor for home use?" Result: Roche Accu-Chek appeared in the response but was not the first recommendation, contributing to the brand's top-three placement without rank-one credit.

Perplexity / Best Blood Glucose Monitors and Diabetes Medical Devices Prompt: "What is the best CGM device?" Result: Roche Accu-Chek received minimal visibility on Perplexity, with only 1 valid recommendation across 26 observations on that platform.

Gemini / Best Blood Glucose Monitors and Diabetes Medical Devices Prompt: "Which CGM device is best?" Result: Roche Accu-Chek achieved its strongest platform-level coverage on Gemini, with a 35.1% valid recommendation rate and 26 valid recommendations.

Google AI Mode / Best Blood Glucose Monitors and Diabetes Medical Devices Prompt: "continuous glucose monitoring" Result: Roche Accu-Chek appeared in the response with positive framing, contributing to its 32 valid recommendations on Google AI Mode.

What CiteWorks Studio Would Do Next

Phase 1: AI Visibility Market Discovery Audit Map the specific prompts where Roche Accu-Chek appears but is not recommended, and identify which competitor takes the recommendation in each case.

Phase 2: Recommendation Readiness Plan Prioritize the prompt clusters and platforms where the brand's presence-to-recommendation conversion gap is widest, starting with Perplexity and ChatGPT.

Phase 3: Owned Answer Layer Buildout Strengthen the brand's product pages, comparison content, and FAQ structures so AI systems can retrieve clear, recommendation-ready answers about Roche Accu-Chek.

Phase 4: Citation / Authority Layer Development Build the third-party validation, review presence, and source footprint that AI systems draw on when forming recommendations, closing the citation gap with Abbott FreeStyle.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track recommendation coverage, top-three rate, and rank-one rate monthly to measure whether the conversion gap is closing.

Why This Matters

AI presence alone is not enough. Roche Accu-Chek is mentioned in nearly 40% of qualified AI responses in its category, but it is recommended in only 28% and placed first in just over 1%. For a buyer asking an AI system which blood glucose monitor to choose, the brand is a supporting option, not the answer. That distinction matters commercially because the recommendation stage is where buyer shortlists are formed and where buyer attention concentrates.

The next move is targeted correction of the prompt, page, and citation layers. The brand does not need more visibility. It needs its existing visibility to convert into recommendation credit, particularly on the high-intent prompts where it already appears. That requires strengthening the owned content that AI systems retrieve, building the third-party source layer that supports recommendation, and tracking whether those changes move the brand from third place toward second.

Core Metrics

Sentiment Score

Questions This Section Answers

• Why do Roche Accu-Chek's 143 mentions not translate into 143 recommendations despite its 0.82 sentiment score?
• What is the difference between sentiment and recommendation for Roche Accu-Chek's AI visibility position?

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Roche Accu-Chek in October 2026: (117 × 1 + 26 × 0 + 0 × -1) / 143 = 0.8182

This score matters because unclassified mention counts are misleading. A brand with 143 mentions could appear to be in a strong position, but if those mentions are neutral references, cautionary comparisons, or competitor-displaced contexts, the brand is not actually being recommended. Roche Accu-Chek's sentiment score of 0.82 indicates that the vast majority of its mentions are positive, which is a genuine asset. However, sentiment is not the same as recommendation. A brand can be mentioned positively as a comparison anchor without being recommended. The sentiment score is a framing quality metric, not a business KPI. It tells you how AI systems talk about the brand, not whether they choose it.

Share of voice is a diagnostic metric, not a business KPI. Counting all mentions as wins is bad measurement. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal. Classified sentiment is required before interpreting AI visibility, and Roche Accu-Chek's classified sentiment is strong. The gap is in recommendation conversion, not in framing.

Sentiment by Platform

Questions This Section Answers

• On which platforms does Roche Accu-Chek receive its strongest positive framing, and where is its presence weakest?
• What does the platform-level sentiment table suggest about where Roche Accu-Chek is mentioned as context rather than recommended?

Methodology

1. Report orientation: This is a benchmark-based AI Visibility Company Market Strategy Report for Roche Accu-Chek in the Healthcare and Medical Devices vertical, produced from the LLM Authority Index October 2026 measurement.
2. Reporting window: October 2026, with comparison to the July 2026 baseline and September 2026 prior-month data where available.
3. Platforms tracked: Six canonical AI/search surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.
4. Observation count: The benchmark began with 681 prompt-surface observations in October 2026, of which 673 were relevant and 363 qualified for the public denominator.
5. Competitor universe: Six brands were tracked: Abbott FreeStyle, Ascensia CONTOUR, Roche Accu-Chek, LifeScan OneTouch, Prodigy Diabetes Care, and Trividia Health.
6. Public clusters used: One cluster with qualified data was included: C01, Best Blood Glucose Monitors and Diabetes Medical Devices. Clusters C02 (Comparisons) and C03 (Pricing and Cost) registered no qualified observations in October 2026.
7. Stage 0 role: Stage 0 extraction produced the prompt-level observations that retain the query, AI surface, answer, brand outcome, recommendation placement, sentiment, and citations where exposed.
8. Definition of a mention: A mention is any qualified observation where the brand appears in the AI response, regardless of whether it is recommended.
9. Definition of a valid recommendation: A valid recommendation is a qualified observation where the brand appears in a recommendation shortlist, as marked by the dataset.
10. Ranking interpretation: Top-three rate measures appearance in the top three recommended positions. Rank-one rate measures appearance as the first recommendation. Average recommended rank covers rank-eligible recommendations only.
11. Limitations: The public benchmark does not measure market share, attributable sales, organic-search ranking, or social mention volume. It does not establish causality from a metric movement alone. The qualified observation count declined from 432 in July to 363 in October even as the raw collection universe expanded, reflecting a growing reserved pool rather than a shrinking category.
12. Dataset note: All brand-level percentages use the 363 qualified observations as the public denominator, not the 681 collected prompts. Small-count brands should be read as directional rather than definitive.

See How AI Is Recommending Your Brand

The public benchmark shows where Roche Accu-Chek stands in AI recommendations across the Healthcare and Medical Devices category. A company-level AI visibility audit maps the specific prompts, platforms, competitors, and citation sources that shape those recommendations, turning the headline coverage figures into a prioritized strategy for closing the gap between presence and recommendation.